Tech Center 1600 • Art Units: 1631 1632 1634 1638
This examiner grants 24% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19361681 | METHODS AND COMPOSITIONS FOR PRODUCING GRANULOSA-LIKE CELLS | Non-Final OA | President and Fellows of Harvard College |
| 18245128 | COMPOSITIONS AND METHODS OF USE FOR INFUSIBLE EXTRACELLULAR MATRIX | Final Rejection | The Regents of the University of California |
| 17830871 | Recombinant Adeno-Associated Virus Products and Methods for Treating Limb Girdle Muscular Dystrophy 2A | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17995687 | CONDITIONING REGIMENS FOR IN VIVO GENE THERAPY | Final Rejection | University of Washington |
| 16794723 | Transcription Factor Mediated Programming Towards Megakaryocytes | Non-Final OA | Cambridge Enterprise Limited |
| 16105625 | METHOD OF PRODUCING THREE-DIMENSIONAL CELL TISSUE | Non-Final OA | TOPPAN Holdings Inc. |
| 18320499 | BIOMATERIALS CONTAINING UMBILICAL CORD-DERIVED STEM CELLS | Final Rejection | GLOBUS MEDICAL, INC. |
| 18029875 | NOVEL NR1 ES-DERIVED NEURAL STEM CELLS HAVING A NORMAL KARYOTYPE AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17416311 | ADENO-ASSOCIATED VIRUSES AND THEIR USES FOR INNER EAR THERAPY | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 16971995 | METHODS AND COMPOSITIONS COMPRISING CART AND A SMAC MIMETIC | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18043095 | ALGINATE-COATED MESENCHYMAL STROMAL AND PROGENITOR CELLS AND METHODS FOR USING THE SAME | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18044288 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | Non-Final OA | University Health Network |
| 17997988 | METHOD FOR DIFFERENTIATING MESENCHYMAL STEM CELLS FROM PLURIPOTENT STEM CELLS | Final Rejection | KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP |
| 16084364 | METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION | Final Rejection | CHILDREN'S MEDICAL CENTER CORPORATION |
| 18301093 | Human Adipose-Derived Stem Cell Exosomes And Their Packaging For Use At Room Temperature | Non-Final OA | The United States Government As Represented By The Department Of Veterans Affairs |
| 17415858 | Gene Therapy for BEST1 Dominant Mutations | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 17042981 | LENTIVIRAL VECTORS FOR HIGH-TITER TRANSDUCTION OF PRIMARY HUMAN CELLS | Final Rejection | University of Massachusetts |
| 17224831 | METHODS OF TREATING INFLAMMATION | Final Rejection | University of South Florida |
| 18051653 | TCF7L2 MEDIATED REMYELINATION IN THE BRAIN | Non-Final OA | University of Rochester |
| 15861124 | Biomimetic Scaffolds Including Devitalized Cells | Final Rejection | University of South Carolina |
| 18382701 | CELL SHEET FOR GENE DELIVERY | Final Rejection | GeneMedicine Co., Ltd. |
| 16333566 | PLURIPOTENT STEM CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF SPINAL CORD INJURY | Final Rejection | Asterias Biotherapeutics, Inc. |
| 18009006 | Treatment of Genetic Dilated Cardiomyopathies | Non-Final OA | Universite d'Evry Val d'Essonne |
| 17680708 | GENE THERAPY USING GENETICALLY MODIFIED VIRAL VECTORS | Final Rejection | BioViva USA, Inc. |
| 17592803 | SYSTEMS AND METHODS FOR GENE THERAPY VIA ADMINISTRATION OF GENETICALLY MODIFIED VIRAL VECTORS | Final Rejection | BioViva USA, Inc. |
| 17674233 | Method of enhancing mobility of stem cells to inflammatory lesion | Non-Final OA | Gachon University of Industry-Academic Cooperation Foundation |
| 17597653 | ONCOLYTIC VIRUS AND APPLICATION THEREOF, AND DRUG FOR TREATING CANCER | Final Rejection | WU, Zetang |
| 16328853 | Provision of a Therapeutically Active Cell Product | Final Rejection | PDI Pharm Development International AG |
| 16322725 | ALLEVIATION AND TREATMENT OF ISCHEMIA REPERFUSION-INDUCED LUNG INJURY USING PLURIPOTENT STEM CELLS | Final Rejection | Mari DEZAWA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy